Related references
Note: Only part of the references are listed.Distinct MRI pattern of pseudoresponse in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review
Lidia Gatto et al.
CLINICAL CASE REPORTS (2021)
Immunotherapy for Glioblastoma: Current Progress and Challenge
Miranda W. Yu et al.
FRONTIERS IN IMMUNOLOGY (2021)
Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients
Bruno Carvalho et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Sue Han et al.
BRITISH JOURNAL OF CANCER (2020)
The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature
Victor M. Lu et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives
Bas Weenink et al.
CANCERS (2020)
Multiple high-grade gliomas: epidemiology, management, and outcome. A systematic review and meta-analysis
Davide Tiziano Di Carlo et al.
NEUROSURGICAL REVIEW (2019)
Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments
Sally L. Perrin et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2019)
Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse
Octavio D. Arevalo et al.
FRONTIERS IN NEUROLOGY (2019)
Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation
Cheila Brito et al.
BMC CANCER (2019)
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Giuseppe Lombardi et al.
LANCET ONCOLOGY (2019)
Current promising treatment strategy for glioblastoma multiform: A review
Sanjib Bahadur et al.
ONCOLOGY REVIEWS (2019)
Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
Annick Desjardins et al.
HEALTH SCIENCE REPORTS (2019)
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study
D. Gramatzki et al.
ANNALS OF ONCOLOGY (2018)
Current Challenges and Opportunities in Treating Glioblastoma
Andrea Shergalis et al.
PHARMACOLOGICAL REVIEWS (2018)
Characterizing Glioblastoma Heterogeneity via Single-Cell Receptor Quantification
Si Chen et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2018)
EGFR as a clinical marker in glioblastomas and other gliomas
Fadi S. Saadeh et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2018)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prognostic Implications of Extent of Resection in Glioblastoma: Analysis from a Large Database
Daniel M. Trifiletti et al.
WORLD NEUROSURGERY (2017)
Current status and future directions of anti-angiogenic therapy for gliomas
Wolfgang Wick et al.
NEURO-ONCOLOGY (2016)
Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients
Afsar Rahbar et al.
ONCOIMMUNOLOGY (2016)
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
Ulrich Herrlinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma
Aurelie Bertaut et al.
ONCOTARGET (2016)
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial
Linda Dirven et al.
EUROPEAN JOURNAL OF CANCER (2015)
Structural and functional features of central nervous system lymphatic vessels
Antoine Louveau et al.
NATURE (2015)
Unsanctifying the sanctuary: challenges and opportunities with brain metastases
Shannon Puhalla et al.
NEURO-ONCOLOGY (2015)
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Kathryn M. Field et al.
NEURO-ONCOLOGY (2015)
Bevacizumab-Induced Hypertension Is a Predictive Marker for Improved Outcomes in Patients With Recurrent Glioblastoma Treated With Bevacizumab
Jim Zhong et al.
CANCER (2015)
The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors?
Kaisorn L. Chaichana et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature
Giuseppe Lombardi et al.
ANTI-CANCER DRUGS (2013)
Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme
R. M. Bambury et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study
Jerrold L. Boxerman et al.
NEURO-ONCOLOGY (2013)
Angiogenesis in Glioblastoma
Sunit Das et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bevacizumab and daily temozolomide for recurrent glioblastoma
Annick Desjardins et al.
CANCER (2012)
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
Matthew Koshy et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
P. Oesterlund et al.
BRITISH JOURNAL OF CANCER (2011)
Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?
Carmen Balana et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2011)
Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors
Woo-Young Kim et al.
FEBS JOURNAL (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma
Paul D. Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors
IJ Torres et al.
NEUROLOGY (2003)
Share Paper
